{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:52:27Z","timestamp":1793425947474,"version":"4.5.0"},"reference-count":127,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,2,7]]},"abstract":"<jats:sec id=\"ab-jrv220022-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Menopause, due to loss of ovarian follicular activity without another pathological or physiological cause, typically occurs between the ages of 45 years and 56 years. During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor symptoms) and more than 50% have genitourinary symptoms (genitourinary syndrome of menopause [GSM]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv220022-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Vasomotor symptoms typically last more than 7 years and GSM is often chronic. Efficacious treatments for women with bothersome vasomotor symptoms or GSM symptoms include hormonal and nonhormonal options. Systemic estrogen alone or combined with a progestogen reduces the frequency of vasomotor symptoms by approximately 75%. Oral and transdermal estrogen have similar efficacy. Conjugated equine estrogens (CEE) with or without medroxyprogesterone acetate (MPA) were the only hormonal treatments for which clinical trials were designed to examine cardiovascular events, venous thromboembolism, and breast cancer risk. Compared with placebo, the increased risk of stroke and venous thromboembolism associated with CEE (with or without MPA) and breast cancer (with use of CEE plus MPA) is approximately 1 excess event\/1000 person-years. Low-dose CEE plus bazedoxifene is not associated with increased risk of breast cancer (0.25%\/year vs 0.23%\/year with placebo). Bioidentical estrogens approved by the US Food and Drug Administration (with identical chemical structure to naturally produced estrogens, and often administered transdermally) also are available to treat vasomotor symptoms. For women who are not candidates for hormonal treatments, nonhormonal approaches such as citalopram, desvenlafaxine, escitalopram, gabapentin, paroxetine, and venlafaxine are available and are associated with a reduction in frequency of vasomotor symptoms by approximately 40% to 65%. Low-dose vaginal estrogen is associated with subjective improvement in GSM symptom severity by approximately 60% to 80%, with improvement in severity by 40% to 80% for vaginal prasterone, and with improvement in severity by 30% to 50% for oral ospemifene.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv220022-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>During the menopausal transition, approximately 50% to 75% of women have vasomotor symptoms and GSM symptoms. Hormonal therapy with estrogen is the first-line therapy for bothersome vasomotor symptoms and GSM symptoms, but nonhormonal medications (such as paroxetine and venlafaxine) also can be effective. Hormone therapy is not indicated for the prevention of cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2022.24140","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:02:54Z","timestamp":1675767774000},"page":"405","source":"Crossref","is-referenced-by-count":334,"title":["Management of Menopausal Symptoms"],"prefix":"10.1001","volume":"329","author":[{"given":"Carolyn J.","family":"Crandall","sequence":"first","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya M.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania"},{"name":"Primary Care Institute, Allegheny Health Network, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn E.","family":"Manson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"jrv220022r1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10654-018-0367-y","article-title":"Body mass index and age at natural menopause.","volume":"33","author":"Zhu","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"jrv220022r2","first-page":"1","article-title":"Research on the menopause in the 1990s.","volume":"866","year":"1996","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"4","key":"jrv220022r3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1210\/jc.2011-3362","article-title":"Executive summary of the Stages of Reproductive Aging Workshop + 10.","volume":"97","author":"Harlow","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"jrv220022r4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0277-9536(00)00147-7","article-title":"Is there a menopausal syndrome?","volume":"52","author":"Avis","year":"2001","journal-title":"Soc Sci Med"},{"issue":"7","key":"jrv220022r5","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","article-title":"Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition.","volume":"96","author":"Gold","year":"2006","journal-title":"Am J Public Health"},{"issue":"4","key":"jrv220022r6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition.","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"10","key":"jrv220022r7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society.","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"issue":"2","key":"jrv220022r8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/GME.0000000000000281","article-title":"Day-to-Day Impact of Vaginal Aging questionnaire.","volume":"22","author":"Huang","year":"2015","journal-title":"Menopause"},{"issue":"2","key":"jrv220022r9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.6118\/jmm.2015.21.2.65","article-title":"The recent review of the genitourinary syndrome of menopause.","volume":"21","author":"Kim","year":"2015","journal-title":"J Menopausal Med"},{"issue":"3","key":"jrv220022r10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jsxm.2017.01.011","article-title":"The Women\u2019s EMPOWER Survey.","volume":"14","author":"Krychman","year":"2017","journal-title":"J Sex Med"},{"issue":"3","key":"jrv220022r11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jama.1995.03520270033028","article-title":"Effects of estrogen or estrogen\/progestin regimens on heart disease risk factors in postmenopausal women.","volume":"273","author":"Miller","year":"1995","journal-title":"JAMA"},{"issue":"7","key":"jrv220022r12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"jrv220022r13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S0015-0282(01)01791-5","article-title":"Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.","volume":"75","author":"Utian","year":"2001","journal-title":"Fertil Steril"},{"issue":"3","key":"jrv220022r14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"14","key":"jrv220022r15","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1775","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy.","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"jrv220022r16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.2010.2016","article-title":"Efficacy of escitalopram for hot flashes in healthy menopausal women.","volume":"305","author":"Freeman","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"jrv220022r17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/AOG.0000000000000927","article-title":"Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms.","volume":"126","author":"Guthrie","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"7","key":"jrv220022r18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1001\/jamainternmed.2014.1891","article-title":"Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms.","volume":"174","author":"Joffe","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"7","key":"jrv220022r19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2016.1795","article-title":"Telephone-based cognitive behavioral therapy for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms.","volume":"176","author":"McCurry","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"5","key":"jrv220022r20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms.","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"4","key":"jrv220022r21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/GME.0000000000000343","article-title":"Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis.","volume":"22","author":"Hodis","year":"2015","journal-title":"Menopause"},{"issue":"9","key":"jrv220022r22","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/GME.0000000000001326","article-title":"The Kronos Early Estrogen Prevention Study (KEEPS).","volume":"26","author":"Miller","year":"2019","journal-title":"Menopause"},{"issue":"13","key":"jrv220022r23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","article-title":"Vascular effects of early versus late postmenopausal treatment with estradiol.","volume":"374","author":"Hodis","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv220022r24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.fertnstert.2012.03.001","article-title":"Effect of escitalopram on hot flash interference.","volume":"97","author":"Carpenter","year":"2012","journal-title":"Fertil Steril"},{"issue":"5","key":"jrv220022r25","doi-asserted-by":"publisher","first-page":"478.e1","DOI":"10.1016\/j.ajog.2019.10.103","article-title":"Obesity, smoking, and risk of vasomotor menopausal symptoms.","volume":"222","author":"Anderson","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"jrv220022r26","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1017\/S003329171100016X","article-title":"Major depression during and after the menopausal transition.","volume":"41","author":"Bromberger","year":"2011","journal-title":"Psychol Med"},{"issue":"7","key":"jrv220022r27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/GME.0000000000000392","article-title":"Poor sleep in relation to natural menopause.","volume":"22","author":"Freeman","year":"2015","journal-title":"Menopause"},{"issue":"3","key":"jrv220022r28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40675-017-0084-1","article-title":"Sleep trajectories before and after the final menstrual period in the Study of Women\u2019s Health Across the Nation (SWAN).","volume":"3","author":"Kravitz","year":"2017","journal-title":"Curr Sleep Med Rep"},{"issue":"8","key":"jrv220022r29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/GME.0000000000001143","article-title":"Menopause versus chronologic aging: their roles in women\u2019s health.","volume":"25","author":"Thurston","year":"2018","journal-title":"Menopause"},{"issue":"12","key":"jrv220022r30","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.5665\/sleep.3244","article-title":"A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep.","volume":"36","author":"Joffe","year":"2013","journal-title":"Sleep"},{"issue":"4","key":"jrv220022r31","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes.","volume":"2004","author":"Maclennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"jrv220022r32","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials.","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"jrv220022r33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality.","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"jrv220022r34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12265-009-9104-y","article-title":"Using basic science to design a clinical trial.","volume":"2","author":"Miller","year":"2009","journal-title":"J Cardiovasc Transl Res"},{"key":"jrv220022r35","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-022-06647-5","article-title":"Effects of transdermal versus oral hormone replacement therapy in postmenopause.","author":"Gold\u0161tajn","journal-title":"Arch Gynecol Obstet"},{"key":"jrv220022r36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/IJWH.S50804","article-title":"Critical appraisal of paroxetine for the treatment of vasomotor symptoms.","volume":"7","author":"Carroll","year":"2015","journal-title":"Int J Womens Health"},{"issue":"9","key":"jrv220022r37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/medicina55090554","article-title":"Efficacy of low-dose paroxetine for the treatment of hot flushes in surgical and physiological postmenopausal women.","volume":"55","author":"Riemma","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"jrv220022r38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/2327-6924.12137","article-title":"The efficacy and tolerability of SSRI\/SNRIs in the treatment of vasomotor symptoms in menopausal women.","volume":"27","author":"Handley","year":"2015","journal-title":"J Am Assoc Nurse Pract"},{"issue":"1","key":"jrv220022r39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11606-013-2535-9","article-title":"SSRIs for hot flashes.","volume":"29","author":"Shams","year":"2014","journal-title":"J Gen Intern Med"},{"issue":"6","key":"jrv220022r40","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ajog.2019.12.011","article-title":"Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms.","volume":"222","author":"Shan","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"jrv220022r41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/2279-042X.117392","article-title":"Comparison of gabapentin with estrogen for treatment of hot flashes in post-menopausal women.","volume":"2","author":"Allameh","year":"2013","journal-title":"J Res Pharm Pract"},{"issue":"4","key":"jrv220022r42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/GME.0000000000001491","article-title":"Gabapentin for the treatment of hot flushes in menopause.","volume":"27","author":"Yoon","year":"2020","journal-title":"Menopause"},{"issue":"3","key":"jrv220022r43","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"issue":"6","key":"jrv220022r44","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/gme.0b013e3181a7df0d","article-title":"Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene\/conjugated estrogens.","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"issue":"5","key":"jrv220022r45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1089\/jwh.2015.5351","article-title":"Gynecologic safety of conjugated estrogens plus bazedoxifene.","volume":"25","author":"Mirkin","year":"2016","journal-title":"J Womens Health (Larchmt)"},{"issue":"1","key":"jrv220022r46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.1994.12.1.155","article-title":"Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.","volume":"12","author":"Goldberg","year":"1994","journal-title":"J Clin Oncol"},{"issue":"10","key":"jrv220022r47","doi-asserted-by":"publisher","first-page":"788","DOI":"10.7326\/0003-4819-132-10-200005160-00004","article-title":"Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes.","volume":"132","author":"Pandya","year":"2000","journal-title":"Ann Intern Med"},{"issue":"17","key":"jrv220022r48","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.2022.18625","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons.","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"jrv220022r49","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/1471-0528.14619","article-title":"Vasomotor symptoms resulting from natural menopause.","volume":"124","author":"Sarri","year":"2017","journal-title":"BJOG"},{"issue":"28","key":"jrv220022r51","doi-asserted-by":"publisher","first-page":"6919","DOI":"10.1200\/JCO.2005.10.081","article-title":"Paroxetine is an effective treatment for hot flashes.","volume":"23","author":"Stearns","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv220022r52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.AOG.0000147840.06947.46","article-title":"Management of postmenopausal hot flushes with venlafaxine hydrochloride.","volume":"105","author":"Evans","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"7","key":"jrv220022r53","article-title":"Acupuncture for menopausal hot flushes.","volume":"2013","author":"Dodin","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"jrv220022r54","article-title":"Relaxation for perimenopausal and postmenopausal symptoms.","author":"Saensak","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"jrv220022r55","article-title":"Phytoestrogens for menopausal vasomotor symptoms.","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"jrv220022r56","article-title":"Exercise for vasomotor menopausal symptoms.","author":"Daley","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"jrv220022r57","article-title":"Black cohosh (Cimicifuga spp.) for menopausal symptoms.","volume":"2012","author":"Leach","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"jrv220022r58","first-page":"498","article-title":"A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause.","volume":"94","author":"Archer","year":"1999","journal-title":"Obstet Gynecol"},{"issue":"20","key":"jrv220022r59","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1161\/CIRCULATIONAHA.105.594077","article-title":"Effects of conjugated equine estrogen on stroke in the Women\u2019s Health Initiative.","volume":"113","author":"Hendrix","year":"2006","journal-title":"Circulation"},{"issue":"7","key":"jrv220022r60","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/archinte.166.7.772","article-title":"Venous thrombosis and conjugated equine estrogen in women without a uterus.","volume":"166","author":"Curb","year":"2006","journal-title":"Arch Intern Med"},{"issue":"13","key":"jrv220022r61","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.2011.382","article-title":"Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy.","volume":"305","author":"LaCroix","year":"2011","journal-title":"JAMA"},{"issue":"9","key":"jrv220022r62","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","article-title":"Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.","volume":"299","author":"Heiss","year":"2008","journal-title":"JAMA"},{"issue":"20","key":"jrv220022r63","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.289.20.2673","article-title":"Effect of estrogen plus progestin on stroke in postmenopausal women.","volume":"289","author":"Wassertheil-Smoller","year":"2003","journal-title":"JAMA"},{"issue":"13","key":"jrv220022r64","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis.","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"jrv220022r65","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.maturitas.2013.06.008","article-title":"Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.","volume":"76","author":"Palacios","year":"2013","journal-title":"Maturitas"},{"issue":"1","key":"jrv220022r66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/aje\/kwp115","article-title":"Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.","volume":"170","author":"Prentice","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"3","key":"jrv220022r67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/aje\/kwaa210","article-title":"Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 years of age.","volume":"190","author":"Prentice","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"13","key":"jrv220022r68","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"jrv220022r69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/GME.0000000000000733","article-title":"Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial.","volume":"24","author":"Chlebowski","year":"2017","journal-title":"Menopause"},{"issue":"6","key":"jrv220022r70","doi-asserted-by":"publisher","first-page":"406","DOI":"10.7326\/M19-0274","article-title":"Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial.","volume":"171","author":"Manson","year":"2019","journal-title":"Ann Intern Med"},{"issue":"5","key":"jrv220022r71","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1210\/clinem\/dgab042","article-title":"Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery.","volume":"106","author":"Shufelt","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"jrv220022r72","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society.","volume":"29","author":"The 2022 Hormone Therapy Position Statement of the North American Menopause Society Advisory Panel","year":"2022","journal-title":"Menopause"},{"issue":"4","key":"jrv220022r73","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.fertnstert.2014.02.043","article-title":"Current recommendations: what is the clinician to do?","volume":"101","author":"Manson","year":"2014","journal-title":"Fertil Steril"},{"issue":"11","key":"jrv220022r74","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline.","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"jrv220022r75","doi-asserted-by":"publisher","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"jrv220022r76","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/GME.0000000000001067","article-title":"Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women\u2019s Health Initiative hormone therapy trials.","volume":"25","author":"Swica","year":"2018","journal-title":"Menopause"},{"issue":"4","key":"jrv220022r77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.7326\/M14-0353","article-title":"Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.","volume":"161","author":"Harman","year":"2014","journal-title":"Ann Intern Med"},{"issue":"5","key":"jrv220022r78","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/EDE.0b013e3181a71279","article-title":"Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women.","volume":"20","author":"Gramling","year":"2009","journal-title":"Epidemiology"},{"issue":"11","key":"jrv220022r79","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians.","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"jrv220022r80","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/archinte.162.6.665","article-title":"Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) safety follow-up study.","volume":"162","author":"Greendale","year":"2002","journal-title":"Arch Intern Med"},{"issue":"13","key":"jrv220022r81","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial.","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"jrv220022r82","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women\u2019s Health Initiative randomized trial.","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"15","key":"jrv220022r83","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1001\/jama.2020.1757","article-title":"The menopause transition and cognition.","volume":"323","author":"Greendale","year":"2020","journal-title":"JAMA"},{"issue":"20","key":"jrv220022r84","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","article-title":"Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women\u2019s Health Initiative Memory Study: a randomized controlled trial.","volume":"289","author":"Shumaker","year":"2003","journal-title":"JAMA"},{"issue":"20","key":"jrv220022r85","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1001\/jama.289.20.2663","article-title":"Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women\u2019s Health Initiative Memory Study: a randomized controlled trial.","volume":"289","author":"Rapp","year":"2003","journal-title":"JAMA"},{"issue":"24","key":"jrv220022r86","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1001\/jama.291.24.2959","article-title":"Conjugated equine estrogens and global cognitive function in postmenopausal women: Women\u2019s Health Initiative Memory Study.","volume":"291","author":"Espeland","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"jrv220022r87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001833","article-title":"Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study.","volume":"12","author":"Gleason","year":"2015","journal-title":"PLoS Med"},{"issue":"15","key":"jrv220022r88","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jamainternmed.2013.7727","article-title":"Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years.","volume":"173","author":"Espeland","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"7","key":"jrv220022r89","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1212\/WNL.0000000000002980","article-title":"Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis.","volume":"87","author":"Henderson","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"jrv220022r90","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.fertnstert.2016.09.046","article-title":"Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause.","volume":"106","author":"Sullivan","year":"2016","journal-title":"Fertil Steril"},{"issue":"4","key":"jrv220022r91","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management.","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric"},{"issue":"1","key":"jrv220022r92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy.","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"issue":"3","key":"jrv220022r93","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jsxm.2015.11.015","article-title":"Role of estrogens and estrogen-like compounds in female sexual function and dysfunction.","volume":"13","author":"Santoro","year":"2016","journal-title":"J Sex Med"},{"issue":"7","key":"jrv220022r94","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.fertnstert.2016.09.018","article-title":"Hormone replacement therapy in young women with surgical primary ovarian insufficiency.","volume":"106","author":"Sarrel","year":"2016","journal-title":"Fertil Steril"},{"key":"jrv220022r95","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis.","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"jrv220022r96","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/13697137.2019.1582622","article-title":"Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.","volume":"22","author":"Vermeulen","year":"2019","journal-title":"Climacteric"},{"issue":"1","key":"jrv220022r97","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations: a systematic review of risks and benefits.","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"4","key":"jrv220022r98","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/cpt1979264502","article-title":"Efficacy of estradiol vaginal cream in postmenopausal women.","volume":"26","author":"Dickerson","year":"1979","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"jrv220022r99","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.gme.0000227401.98933.0b","article-title":"A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women.","volume":"13","author":"Long","year":"2006","journal-title":"Menopause"},{"issue":"4","key":"jrv220022r100","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/gme.0b013e3181a48c4e","article-title":"Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally.","volume":"16","author":"Bachmann","year":"2009","journal-title":"Menopause"},{"issue":"4","key":"jrv220022r101","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/AOG.0b013e3181f386bb","article-title":"Endometrial safety of ultra-low-dose estradiol vaginal tablets.","volume":"116","author":"Simon","year":"2010","journal-title":"Obstet Gynecol"},{"key":"jrv220022r102","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105360","article-title":"Efficacy and safety of current therapies for genitourinary syndrome of menopause: a bayesian network analysis of 29 randomized trials and 8311 patients.","volume":"164","author":"Li","year":"2021","journal-title":"Pharmacol Res"},{"issue":"13","key":"jrv220022r103","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/14656566.2021.1921148","article-title":"Pharmacotherapeutic options for the treatment of menopausal symptoms.","volume":"22","author":"Genazzani","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"jrv220022r104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001500.pub3","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women.","volume":"2016","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv220022r105","first-page":"45","article-title":"Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.","volume":"10","author":"Pinkerton","year":"2003","journal-title":"Menopause"},{"issue":"1","key":"jrv220022r106","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0378-5122(89)90120-5","article-title":"Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy.","volume":"11","author":"Holmgren","year":"1989","journal-title":"Maturitas"},{"key":"jrv220022r107","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jsbmb.2015.08.016","article-title":"Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.","volume":"154","author":"Ke","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"jrv220022r108","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jsbmb.2016.03.016","article-title":"Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.","volume":"159","author":"Martel","year":"2016","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"jrv220022r109","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/GME.0000000000000428","article-title":"Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).","volume":"22","author":"Archer","year":"2015","journal-title":"Menopause"},{"issue":"12","key":"jrv220022r110","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/GME.0000000000000470","article-title":"Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.","volume":"22","author":"Portman","year":"2015","journal-title":"Menopause"},{"issue":"3","key":"jrv220022r111","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/GME.0000000000000571","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.","volume":"23","author":"Labrie","year":"2016","journal-title":"Menopause"},{"issue":"11","key":"jrv220022r112","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1097\/GME.0000000000001238","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.","volume":"25","author":"Labrie","year":"2018","journal-title":"Menopause"},{"issue":"4","key":"jrv220022r113","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"issue":"2","key":"jrv220022r114","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climacteric"},{"issue":"2","key":"jrv220022r115","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","article-title":"Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.","volume":"78","author":"Portman","year":"2014","journal-title":"Maturitas"},{"issue":"3","key":"jrv220022r116","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"issue":"1","key":"jrv220022r117","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00192-020-04397-z","article-title":"Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials.","volume":"32","author":"Chen","year":"2021","journal-title":"Int Urogynecol J"},{"issue":"9","key":"jrv220022r118","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/archinternmed.2012.777","article-title":"Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women.","volume":"172","author":"Beerepoot","year":"2012","journal-title":"Arch Intern Med"},{"issue":"11","key":"jrv220022r119","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1086\/374341","article-title":"Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women.","volume":"36","author":"Raz","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"jrv220022r120","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/SPV.0000000000000244","article-title":"Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women: a systematic review.","volume":"22","author":"Due\u00f1as-Garcia","year":"2016","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"3","key":"jrv220022r121","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.maturitas.2013.12.005","article-title":"Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.","volume":"77","author":"Simon","year":"2014","journal-title":"Maturitas"},{"issue":"6","key":"jrv220022r122","first-page":"2757","article-title":"Serum lipid profile improved by ultra-low doses of 17\u00df-estradiol in elderly women.","volume":"86","author":"Naessen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"jrv220022r123","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/GME.0000000000000786","article-title":"The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.","volume":"24","author":"Constantine","year":"2017","journal-title":"Menopause"},{"issue":"5","key":"jrv220022r124","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/jog.2001.27.issue-5","article-title":"The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study.","volume":"27","author":"Manonai","year":"2001","journal-title":"J Obstet Gynaecol Res"},{"key":"jrv220022r125","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/0378-5122(95)00963-9","article-title":"Clinical trial of the estradiol vaginal ring in the US.","volume":"22","author":"Nachtigall","year":"1995","journal-title":"Maturitas"},{"issue":"1","key":"jrv220022r127","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/GME.0000000000000275","article-title":"Endometrial safety of ospemifene: results of the phase 2\/3 clinical development program.","volume":"22","author":"Constantine","year":"2015","journal-title":"Menopause"},{"key":"jrv220022r50","volume-title":"The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use","author":"National Academies of Sciences, Engineering, and Medicine","year":"2020"},{"key":"jrv220022r126","unstructured":"National Library of Medicine DailyMed. Drug label information for VAGIFEM-estradiol insert. Accessed January 18, 2023. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e5ad3cf6-dd96-4e64-af21-c1eee38d0b88?"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2801054\/jama_crandall_2023_rv_220022_1674761919.62764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:03:13Z","timestamp":1675767793000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2801054"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":127,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,2,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.24140","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,7]]}}}